Dissolution properties and characterization of halofantrine-2- hydroxypropyl-β-cyclodextrin binary systems

Pharmazie

Volumn 62, Issue 11, 2007, Pages 858-863

  Onyeji, Cyprian O ^a   Omoruyi, S I ^a   Oladimeji, F A ^a  

^a OBAFEMI AWOLOWO UNIVERSITY   (Nigeria)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLODEXTRIN; HALOFANTRINE 2 HYDROXYPROPYL BETA CYCLODEXTRIN; METHANOL DERIVATIVE; PHENANTHRENE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; DRUG SOLUBILITY; DRUG STRUCTURE; INFRARED SPECTROSCOPY; STOICHIOMETRY; X RAY DIFFRACTION;

BETA-CYCLODEXTRINS; CRYSTALLOGRAPHY, X-RAY; FREEZE DRYING; INDICATORS AND REAGENTS; KINETICS; PHENANTHRENES; SOLUBILITY; SPECTROPHOTOMETRY, INFRARED; WATER;

EID: 36349029084     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2007.11.7081     Document Type: Article

References (29)

1. Abdul-Fattah AM, Bhargava HN (2002) Preparation and in vitro evaluation of solid dispersions of halofantrine. Int J Pharm 235: 17-33.
2. Ajayi FO, Fleckenstein LL (1994) Intramuscular toxicity and absorbance of parenteral formulation of halofantrine HCl. Clin Res Reg Aff 11: 193-205.
3. Baboota S, Dhaliwal M, Kohli K (2005) Physicochemical characterization, in vitro dissolution behaviour and pharmacodynamic studies of rofecoxib hydroxypropyl beta-cyclodextrin inclusion complex: A technical note. AAPS Pharm Sci Tech 6: E83-E89.
4. Bouchaud O, Basko LK, Gillotin C, Gimenez F, Ramiliarisoa O, Genissel B, Bavet E (1994) Clinical efficacy and pharmacokinetics of micronized halofantrine for the treatment of acute uncomplicated falciparum malaria in nonimmune patients. Am J Trop Med Hyg 51: 204-213.
5. British Pharmacopoeia (1988) Her Majesty's Stationery Office. London. United Kingdom.
6. Bryson HM, Goa KL (1992) Halofantrine: A review of its antimalarial activity, pharmacokinetics properties and therapeutic potential. Drugs 43: 236-258.
7. Charman WN (1997) Lipids, lymph and lipidic formulations. Bull Tech Gattefosse 90: 27-32.
8. Connors KA (1997) The stability of cyclodextrin complexes in solution. Chem Review 97: 1325-1357.
9. Corringan OI, Stanley T (1982) Mechanism of drug dissolution rate enhancement from beta-cyclodextrin-drug-systems. J Pharm Sci 34: 621-626.
10. Fernandes CM, Teresa Vieira M, Veiga FJ (2002) Physicochemical characterization and in vitro dissolution behavior of nicardipine-cyclodextrins inclusion compounds. Eur J Pharm Sci 15: 79-88.
11. Higuchi T, Connors KA (1965) Phase solubility diagram. Adv Anal Chem Instrum 4: 17-21.
12. Illapakurthy AC, Sabnis YA, Avery BA, Mitchell A, Avery MA, Wyandt CA (2003) Interaction of artemisinin and its related compounds with hydroxypropyl-β-cyclodextrin in solution state: Experimental and molecular-modeling studies. J Pharm Sci 92: 649-655.
13. Karbwang J, Milton KA, Na-Bangchang K, Ward SA, Edwards G, Bunnag D (1991) Pharmacokinetics of halofantrine in Thai patients with acute uncomplicated falciparum malaria. Br J Clin Pharmacol 31: 484-487.
14. Karbwang J, Na-Bangchang K (1994) Clinical pharmacokinetics of halofantrine. Clin Pharmacokinet 27: 104-119.
15. Khoo SM, Porter CJ, Charman WN (2000) The formulation of halofantrine as either non-solubilizing PEG 6000 or solubilizing lipid-based solid dispersions: physical stability and absolute bioavailability assessment. Int J Pharm 205: 65-78.
16. Loftson T, Brewster ME (1996) Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci 85: 1017-1025.
17. Manca ML, Zaru M, Ennas G, Valenti D, Sinico C, Loy G, Fadda AM (2005) Diclofenac-beta-cyclodextrin binary systems: physicochemical characterization and in vitro dissolution and diffusion studies. AAPS Pharm Sci Tech 6: E464-E472
18. Milton KA, Edwards G, Ward SA, Orme ML, Breckenridge AM (1989) Pharmacokinetics of halofantrine: effects of food and dose size. Br J Clin Pharmacol 28: 71-77.
19. Nallury BN, Chowdary KP, Murthy KV, Hayman AR, Becker G (2003) Physicochemical characterization and dissolution properties of numesulide-cyclodextrin binary systems. AAPS Pharm Sci Tech 4: 1-12.
20. Oht C, Watt G, Teja-Isvadharm P, Keeratithakul D, Loesuttiviboon L, Kyle H, Webster K, Schuster B, Fleckenstein L (1995) Pharmacokinetics of an extended dose regimen in patients with malaria and healthy volunteers. Clin Pharmacol Ther 57: 525-532.
21. Pose-Vilarnovo B, Perdomo-Lopez I, Echezarreta-Lopez M, Schoth-Pardo P, Estrada E, Torres-Labandeira JJ (2001) Improvement of water solubility of sulfamethizole though its complexation with beta- and hydroxypropyl-beta- cyclodextrin. Characterization of the interaction in solution and in solid state. Eur J Pharm Sci 13: 325-331.
22. Reddy MN, Rehana T, Ramakrishna S, Chowdary KPR, Diwan PV (2004) β-Cyclodextrin compleces of celecoxib: molecular-modeling, characterization, and dissolution studies. AAPS Pharm Sci 6: article 7. DOI: 10.1208/ps060107.
23. Ryan JA (1986) Compressed pellet x-ray diffraction monitoring for optimization of crystallinity in lyophilized solids: imipenemxilastin sodium case. J Pharm Sci 75: 805-807.
24. Stella VJ, Rajiwski RA (1997) Cyclodextrins: Their future in drug formulation and delivery. Pharm Res 14: 556-567.
25. Szejtli J (1994) Medicinal applications of cyclodextrins. Med Res Rev 14: 353-386.
26. Trapani G, Latrofa A, Franco M (2000) Complexation of zolpiden with 2-hydroxypropyl-b-, methyl-b-, and 2-hydroxypropyl-g-cyclodextrin: Effect on aqueous solubility, dissolution rate and ataxic activity in rat. J Pharm Sci 89: 1443-1451.
27. Uekama K, Hirayama F (1996) Improvement of drug properties by cyclodextrin. In: Wermuth CG (ed.) The Practice of Medicinal Chemistry. Academic Press, London, pp. 793-825.
28. Vlachou M, Papioannou G (2003) Preparation and characterization of inclusion complex of furosemide with hydroxypropyl-beta-cyclodextrin. J Biomater Appl 17: 197-206.
29. Yamada Y, Imal T, Ouchi K, Otagiri M, Hirayam F, Eukama K (2000) Inclusion complex of 3,9-bis(N,N-dimethylcarbomoyloxy)5H-benzofuro [3,2-c]-quinoline-6-one (kc A-098) with heptakis(2,6-di-O-methyl) -β-cyclodextrin: interaction and dissolution properties. Chem Pharm Bull 48: 1264-1268.